Knightway Capital
Knightway Capital is a global investment firm focusing on med-tech, fin-tech, and legal-tech investments. We commit people, knowledge, and capital to empower revolutionary ideas and help exceptional entrepreneurs build enterprises contributing to the common good and long-term prosperity of society.
We are founded by a team of experienced professionals and executives with extensive industry expertise and backed by the most connected and influential investors and partners in the business ecosystem.
We are founded by a team of experienced professionals and executives with extensive industry expertise and backed by the most connected and influential investors and partners in the business ecosystem.
Cheng Charles
PartnerKymeris therapeutics Inc
Kymeris has invented a revolutionary, live-cell based technology platform which delivers into the tumor micro-environment and activates there multiple therapeutic agents - including ligands, cytokines, and antibodies. Efficacy of anti-cancer action has been shown in 5 separate solid cancer indications with reduction in tumour size averaging 80% - but in many cases showing complete eradication. This game changing approach is of particular value to companies with proprietary molecules that are looking for safe and effective vectoring into tumors, and with whom we might partner.
Mr. Richard McCrae
President & CEOLauren Craig Consulting LLC
Consulting services with expertise in sales, business development and market access.
Ms. Lauren Craig, MBA CPC-H
FounderLeibniz-Institut fuer Analytische Wissenschaften - ISAS
Our goal is to advance the development of analytical technologies by combining our specialist knowledge from chemistry, biology, physics and computer science and the transfer of our results to science, business and the public are our main goals.
Suyuan Chen
Research associateLEO Pharma
Founded in 1908, LEO Pharma is an independent, research-based pharmaceutical company, wholly owned by The LEO Foundation and is headquartered in Ballerup, Denmark. LEO Pharma is a leader in medical dermatology and developes, manufactures and markets pharmaceutical drugs for medical dermatology and thrombosis in more than 100 countries globally. We offer patients and physicians highly innovative and well-established products in Psoriasis, Atopic Dermatitis, Acne, Rosacea, and Actinic keratosis. LEO Pharma is continously striving to advance innovation to bring best-in-class and first-in-class medicines in medical dermatology and rare dermatological diseases to create a solid pipeline of assets.
LEO Pharma’s mission is to provide people with healthy skin and is has a global dermatology reach employing approximately 6,000 employees worldwide. We serve approximately 92 million patients in 2019 with ambition to serve 125 million patients by 2025.
To realize our vision of becoming the preferred dermatology care partner improving people’s lives around the world, we are constantly looking to collaborate with other companies, Universities to offer patients with therapies that address unmet medical needs in dermatology.
We are keen for Licensing-in Assets for Global and Regional Rights for following:
(1) Chinese Rights: innovative (first-in-class or best-in-class) late stage assets (Phase 3 or launched in US, EU or Japan) in medical dermatology or rare dermatological diseases
(2) Global Rights: innovative (first-in-class or best-in-class) assets (Pre-clinical through phase III) in medical dermatology or rare dermatological diseases from Asian Biotech companies, Research, and/or academic institutes/universities.
(3) VC companies: Who have in their portfolio, companies that have medical dermatology products in their pipeline for China or Global markets
(4) Keen to Science and Tech parks in China: Who have companies conducting cutting edge research in medical dermatology
LEO Pharma’s mission is to provide people with healthy skin and is has a global dermatology reach employing approximately 6,000 employees worldwide. We serve approximately 92 million patients in 2019 with ambition to serve 125 million patients by 2025.
To realize our vision of becoming the preferred dermatology care partner improving people’s lives around the world, we are constantly looking to collaborate with other companies, Universities to offer patients with therapies that address unmet medical needs in dermatology.
We are keen for Licensing-in Assets for Global and Regional Rights for following:
(1) Chinese Rights: innovative (first-in-class or best-in-class) late stage assets (Phase 3 or launched in US, EU or Japan) in medical dermatology or rare dermatological diseases
(2) Global Rights: innovative (first-in-class or best-in-class) assets (Pre-clinical through phase III) in medical dermatology or rare dermatological diseases from Asian Biotech companies, Research, and/or academic institutes/universities.
(3) VC companies: Who have in their portfolio, companies that have medical dermatology products in their pipeline for China or Global markets
(4) Keen to Science and Tech parks in China: Who have companies conducting cutting edge research in medical dermatology
Mr Rachit Vohra
Business Development DIrectorLibera Bio
Libera Bio develops a new family of cancer treatments based on its patented actively targeted delivery technology to intracellular targets (MPN – Multifunctional Polymeric Nanocapsules) and on novel monoclonal antibodies (e.g. anti KRAS), with the goal to have them commercialized by large biopharma companies after regulatory approval for clinical trials or early proof-of-concept in humans.
Libera Bio lead candidate aims at providing a new treatment for those highly prevalent and aggressive cancers which are driven by KRAS mutations, such as pancreatic cancer, lung cancer and colorectal cancer.
Libera Bio lead candidate aims at providing a new treatment for those highly prevalent and aggressive cancers which are driven by KRAS mutations, such as pancreatic cancer, lung cancer and colorectal cancer.
Olivier Jarry
MS, MBALinkedUp Bioscience
LinkedUp Bio, pioneered a novel antibody drug discovery engine that is dedicated to developing novel biological therapeutics for diseases that have limited or no successful treatment.
The gamechanger element is that we can scree the entire natural immune repertoire with unprecedented speed and scales and identified hits rapidly and efficiently, thereby greatly increasing the success rate of potential therapeutics for targets that are hard to drug.
AbLink Platform: Screening the entire immune repertoire for more efficient antibody discovery
LInkedUp Bio is using microfluidic device to enable single B cell encapsulation, and subsequently, extract the information of heavy chain and light chain of antibody from tens of millions of B cells and then transferred them into our in-house engineered yeast system. These antibody copies in the yeast cells maintained their natural heavy chaiin and light chain pair, and good biophysical stabilities of the original B cells. Our yeast strain has both display and secretion mode which enables quick chacterization of the potential hits, eliminating the step for mamamlian expression for further hits validation, a typical bottleneck for many single B cell platfrom.
The AbLink Platform is the only platform allowing comprehensive screening of the natural antibody repertoire. This results in at least 100 times more hits than hybridoma and other single B cell platforms. Other benefits include more extensive epitope coverage, more unique and rare sequences & diversity, higher affinity, and functionality. Currently the platform gathered a great deal of interest in industry as we already collaborated with two biopharmas and several others are in the middle of conversation.
LUB-001 : Tackling malignant melanoma and solid tumors
LinkedUp Bio’s first target indication is malignant melanoma, one of the deadliest forms of human cancer, due to the high incidence of metastases and drug resistance. Extensive research supports the role of a new target X for malignant melanoma, potentially affecting tumor growth, survival and metastasis. However, due to the limitations of traditional antibody discovery technologies and the complex structure of the target, there have been numerous antibody candidates that showed limited efficacy in inhibition of tumor growth, never matched the high expectation and promise of a breakthrough treatment.
LinkedUp developed a novel antibody clone for this target X and in vitro data demonstrated drastically improvement of the ability of the immune system to attack the tumor cells. LinkedUp Bio’s approach can provide a novel promising treatment for many different types of cancer, such as triple negative breast cancer, glioblastoma, hepatocellular carcinoma, and more.
LUB-002: Tackling congenital muscular dystrophy
Alpha Dystrolycanopathy is a clinically and genetically heterogeneous group of muscular dystrophies with the defective matriglycan which links the muscle cells with extracellular matrix . The cause of the defection involved more than 18 genes, and manifested various degree of severity in clinical symptoms. Currently there no effective therapy for this group of diseases. Novel strategies like antisense, AAV gene therapy, enzyme replace can only address one kind gene a time, making a significant commercial challenge. We propose a novel bispecific antibody approach that functions as a surrogate molecular linker to reconnect extracelluar matrix and the muscle cells to ameliorate sarcolemmal fragility, a primary pathology in patients with alpha-dystroglycan- related muscular dystrophies.
We are currently seeking fund to move our program forward and expand our team.
Team:
Greg Li, Co-founder, President
Stephen Gillies, Co-founder, CSO
Tao Wang, Co-founder, Vice President of Antibody Discovery
Jason Lavinder, Cofounder, Advisory Board
The gamechanger element is that we can scree the entire natural immune repertoire with unprecedented speed and scales and identified hits rapidly and efficiently, thereby greatly increasing the success rate of potential therapeutics for targets that are hard to drug.
AbLink Platform: Screening the entire immune repertoire for more efficient antibody discovery
LInkedUp Bio is using microfluidic device to enable single B cell encapsulation, and subsequently, extract the information of heavy chain and light chain of antibody from tens of millions of B cells and then transferred them into our in-house engineered yeast system. These antibody copies in the yeast cells maintained their natural heavy chaiin and light chain pair, and good biophysical stabilities of the original B cells. Our yeast strain has both display and secretion mode which enables quick chacterization of the potential hits, eliminating the step for mamamlian expression for further hits validation, a typical bottleneck for many single B cell platfrom.
The AbLink Platform is the only platform allowing comprehensive screening of the natural antibody repertoire. This results in at least 100 times more hits than hybridoma and other single B cell platforms. Other benefits include more extensive epitope coverage, more unique and rare sequences & diversity, higher affinity, and functionality. Currently the platform gathered a great deal of interest in industry as we already collaborated with two biopharmas and several others are in the middle of conversation.
LUB-001 : Tackling malignant melanoma and solid tumors
LinkedUp Bio’s first target indication is malignant melanoma, one of the deadliest forms of human cancer, due to the high incidence of metastases and drug resistance. Extensive research supports the role of a new target X for malignant melanoma, potentially affecting tumor growth, survival and metastasis. However, due to the limitations of traditional antibody discovery technologies and the complex structure of the target, there have been numerous antibody candidates that showed limited efficacy in inhibition of tumor growth, never matched the high expectation and promise of a breakthrough treatment.
LinkedUp developed a novel antibody clone for this target X and in vitro data demonstrated drastically improvement of the ability of the immune system to attack the tumor cells. LinkedUp Bio’s approach can provide a novel promising treatment for many different types of cancer, such as triple negative breast cancer, glioblastoma, hepatocellular carcinoma, and more.
LUB-002: Tackling congenital muscular dystrophy
Alpha Dystrolycanopathy is a clinically and genetically heterogeneous group of muscular dystrophies with the defective matriglycan which links the muscle cells with extracellular matrix . The cause of the defection involved more than 18 genes, and manifested various degree of severity in clinical symptoms. Currently there no effective therapy for this group of diseases. Novel strategies like antisense, AAV gene therapy, enzyme replace can only address one kind gene a time, making a significant commercial challenge. We propose a novel bispecific antibody approach that functions as a surrogate molecular linker to reconnect extracelluar matrix and the muscle cells to ameliorate sarcolemmal fragility, a primary pathology in patients with alpha-dystroglycan- related muscular dystrophies.
We are currently seeking fund to move our program forward and expand our team.
Team:
Greg Li, Co-founder, President
Stephen Gillies, Co-founder, CSO
Tao Wang, Co-founder, Vice President of Antibody Discovery
Jason Lavinder, Cofounder, Advisory Board